首页> 美国卫生研究院文献>Pharmaceuticals >Structure-Based Virtual Screening and De Novo Design of PIM1 Inhibitors with Anticancer Activity from Natural Products
【2h】

Structure-Based Virtual Screening and De Novo Design of PIM1 Inhibitors with Anticancer Activity from Natural Products

机译:基于结构的虚拟筛选和PIM1抑制剂与天然产品抗癌活动的DE Novo设计

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: the proviral insertion site of Moloney murine leukemia (PIM) 1 kinase has served as a therapeutic target for various human cancers due to the enhancement of cell proliferation and the inhibition of apoptosis. Methods: to identify effective PIM1 kinase inhibitors, structure-based virtual screening of natural products of plant origin and de novo design were carried out using the protein–ligand binding free energy function improved by introducing an adequate dehydration energy term. Results: as a consequence of subsequent enzyme inhibition assays, four classes of PIM1 kinase inhibitors were discovered, with the biochemical potency ranging from low-micromolar to sub-micromolar levels. The results of extensive docking simulations showed that the inhibitory activity stemmed from the formation of multiple hydrogen bonds in combination with hydrophobic interactions in the ATP-binding site. Optimization of the biochemical potency by chemical modifications of the 2-benzylidenebenzofuran-3(2H)-one scaffold led to the discovery of several nanomolar inhibitors with antiproliferative activities against human breast cancer cell lines. Conclusions: these new PIM1 kinase inhibitors are anticipated to serve as a new starting point for the development of anticancer medicine.
机译:背景:莫尼鼠白血病(PIM)1激酶的透过插入部位已经用作各种人类癌症的治疗靶标,这是由于细胞增殖的增强和对细胞凋亡的抑制作用。方法:为了鉴定有效的PIM1激酶抑制剂,使用蛋白质 - 配体通过引入足够的脱水能量术语来进行植物来源的天然产物和DE Novo设计的基于结构的虚拟筛选。结果:由于随后的酶抑制测定,发现了四种类别的PIM1激酶抑制剂,其生化效力从低微摩拉到亚微摩尔水平。广泛对接模拟的结果表明,抑制活性源于多个氢键的形成,与ATP结合位点的疏水相互作用组合。通过2-苄基苯并呋喃-3(2H)的化学改性优化生化效力 - 酮支架导致对人乳腺癌细胞系的抗增殖活动的几种纳米摩尔抑制剂的发现。结论:预计这些新的PIM1激酶抑制剂是抗癌医学发展的新起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号